Top Markets
#1 Velas Velas +367.72%
#2 Gravity Gravity +48.70%
#3 Galxe Galxe +41.28%
#4 Infinity Ground Infinity Ground +30.80%
#5 Wiki Cat Wiki Cat +26.84%
#6 Audiera Audiera +26.57%
#7 Fetch.ai Fetch.ai +26.24%
#8 Derive Derive +24.86%
#9 Aria.AI Aria.AI +20.75%
#10 Babylon Babylon +18.83%
Coin of the day
Velas Velas
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Kedudukan dalam Saham #96
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Harga Saham
$38.41
Modal Pasaran
$170.67B
Perubahan (1 hari)
1.17%
Perubahan (1 tahun)
-49.92%
Negara
DK
Perdagangan Novo Nordisk A/S (NVO)

Kategori

Healthcare
Permodalan Pasaran
Pendapatan
lagi
Keuntungan
Sejarah Harga
Nisbah P/E
Nisbah P/S
Nisbah P/B
Margin Operasi
EPS
Pecahan Saham
Dividen
Hasil Dividen
Saham Terbitan
Pendapatan untuk Novo Nordisk A/S (NVO)
Pendapatan pada Dec 2025 TTM: $20.51B
Menurut laporan kewangan terkini Novo Nordisk A/S, pendapatan semasa syarikat ialah $20.51B. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Novo Nordisk A/S dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -77.36%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -74.49%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -89.57%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -92.13%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -92.92%
NL